Menumenu
  • Home
  • Resource Library

Resource Library

publications • bibliographies • white papers

All Publications

  • Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the NetherlandsAbstract

    BACKGROUND: Most randomised clinical trials typically exclude a significant proportion of asthma patients, including those at higher risk of adverse events, with comorbidities, obesity, poor inhaler technique and adherence, or smokers. However, thee patients might differentially benefit from extrafine-particle inhaled corticosteroids (ICS)

    van der Molen T, Postma DS, Martin RJ, Herings RM, Overbeek JA, Thomas V, Miglio C, Dekhuijzen R, Roche N, Guilbert T, Israel E, van Aalder en W, Hillyer EV, van Rysewyk S, Price DB. BMC Pulm Med. 2016 16 80.
  • Non-adherence to inhaled corticosteroids and the risk of asthma exacerbations in childrenAbstract

    BACKGROUND: Non-adherence to inhaled corticosteroids (ICSs) is a major risk factor for poor asthma control in children. However, little is known about the effect of adherence to ICS on the incidence of asthma exacerbations. The objective of this stdy was to examine the effect of poor adherence to ICS on the risk of exacerbations in children with asthma

    Vasbinder EC, Belitser SV, Souverein PC, van Dijk L, Vulto AG, van den Bemt PM. Patient Prefer Adherence. 2016 10 531-8.
  • Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal DetectionAbstract

    BACKGROUND AND OBJECTIVE: Spontaneous reporting systems (SRSs) remain the cornerstone of post-marketing drug safety surveillance despite their well-known limitations. Judicious use of other available data sources is essential to enable better detecion, strengthening and validation of signals. In this study, we investigated the potential of electronic healthcare records (EHRs) to be used alongside an SRS as an independent system, with the aim of improving signal detection

    Pacurariu AC, Straus SM, Trifiro G, Schuemie MJ, Gini R, Herings R, Mazzaglia G, Picelli G, Scotti L, Peder sen L, Arlett P, van der Lei J, Sturkenboom MC, Coloma PM. Drug Saf. 2015 Dec; 38 1201-10.
  • Infants born before 32 weeks of gestation or with respiratory disease are most likely to receive palivizumab in the NetherlandsAbstract

    AIM: Palivizumab is reported to be effective in reducing respiratory syncytial virus hospitalisation. Its licensed uses include infants younger than six months of age, born before 35 weeks of gestation or under two years old with congenital heart dsease or bronchopulmonary dysplasia. We redressed lack of research in the Netherlands by studying whether infants who met the licensed indications received the drug

    Kool-Houweling LM, Penning-van Beest FJ, Bezemer ID, van Lingen RA, Herings RM. Acta Paediatr. 2015 Sep; 104 927-32.
  • The role of electronic healthcare record databases in paediatric drug safety surveillance: a retrospective cohort studyAbstract

    AIM: Electronic healthcare record (EHR)-based surveillance systems are increasingly being developed to support early detection of safety signals. It is unknown what the power of such a system is for surveillance among children and adolescents. In tis paper we provide estimates of the number and classes of drugs, and incidence rates (IRs) of events, that can be monitored in children and adolescents (0-18 years)

    deBie S, Coloma PM, Ferrajolo C, Verhamme KM, Trifiro G, Schuemie MJ, Straus SM, Gini R, Herings R, Mazzaglia G, Picelli G, Ghirardi A, Peder sen L, Stricker BH, van der Lei J, Sturkenboom MC, consortium Eu-Adr. Br J Clin Pharmacol. 2015 Aug; 80 304-14.
  • Long term trends in oral antidiabetic drug use among children and adolescents in the NetherlandsAbstract

    AIM: The aim of the study was to document long term trends in oral antidiabetic drug (OAD) use among children and adolescents in the Netherlands. METHODS: A population-based cohort study was conducted using the Dutch PHARMO Database Network. All paients younger than 20 years old with at least one OAD dispensing were identified

    FazeliFarsani S, Souverein PC, Overbeek JA, van der Vorst MM, Knibbe CA, Herings RM, deBoer A, Mantel-Teeuwisse AK. Br J Clin Pharmacol. 2015 Aug; 80 294-303.
  • Chronic comorbidities in children with type 1 diabetes: a population-based cohort studyAbstract

    OBJECTIVE: To determine the incidence of chronic comorbidities among children with type 1 diabetes (T1D) and to compare incidences with a group of children without diabetes. DESIGN: Population-based cohort study. SETTING: Dutch PHARMO database (199-2010). PATIENTS: All patients (<19 years old) with T1D between 1999 and 2009 (T1D cohort) and a group of age- and sex-matched (ratio: 1-4) children without diabetes (reference cohort)

    FazeliFarsani S, Souverein PC, van der Vorst MM, Knibbe CA, deBoer A, Mantel-Teeuwisse AK. Arch Dis Child. 2015 Aug; 100 763-8.
  • Trends in paediatric macrolide use in five European countries-a population-based studyAbstract

    PURPOSE: The study aims to analyse overall as well as subgroup-specific outpatient paediatric macrolide use in five European countries, including time trends of macrolide prescription rates, and to provide potential targets for future interventionsaiming to promote judicious macrolide use. METHODS: Macrolide prescription rates per 1000 person years to paediatric outpatients (

    Holstiege J, Ender s D, Schink T, Innocenti F, Oteri A, Bezemer I, Kaguelidou F, Molokhia M, Poluzzi E, Puccini A, Ulrichsen SP, Sturkenboom MC, Trifiro G, Garbe E. Eur J Clin Pharmacol. 2015 Aug; 71 991-9.
  • Antibiotic use varies substantially among adults: a cross-national study from five European Countries in the ARITMO projectAbstract

    PURPOSE: To examine patterns of outpatient and community antibiotic use among adults in five European countries. METHODS: We used healthcare data of 28.8 million adults from six population-based ARITMO project databases to ascertain information onystemic antibiotic use in Denmark (2000-2008), the Netherlands (1999-2010), Italy (2000-2010), the UK (1996-2009), and Germany (2004-2008)

    Mor A, Froslev T, Thomsen RW, Oteri A, Rijnbeek P, Schink T, Garbe E, Pecchioli S, Innocenti F, Bezemer I, Poluzzi E, Sturkenboom MC, Trifiro G, Sogaard M. Infection. 2015 Aug; 43 453-72.
  • Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another?Abstract

    BACKGROUND: Metformin, statin and aspirin use seem associated with decreased mortality in cancer patients, though, without adjusting for one another. Independent associations of these drugs with overall mortality after colorectal cancer (CRC) diagnsis within glucose-lowering drugs (GLDs) users were assessed

    Zander s MM, van Herk-Sukel MP, Vissers PA, Herings RM, Haak HR, van dePoll-Franse LV. Br J Cancer. 2015 Jul 28; 113 403-10.